Research Analysts Offer Predictions for ARWR Q2 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will earn ($0.32) per share for the quarter, up from their prior forecast of ($0.54). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($2.14) EPS.

A number of other equities research analysts have also issued reports on ARWR. Citigroup dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. Sanford C. Bernstein lowered their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. B. Riley reiterated a “buy” rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $41.44.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $19.95 on Thursday. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The business has a 50 day simple moving average of $20.00 and a 200-day simple moving average of $21.16. The firm has a market capitalization of $2.50 billion, a PE ratio of -3.97 and a beta of 0.95. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $36.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97).

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Schonfeld Strategic Advisors LLC raised its stake in shares of Arrowhead Pharmaceuticals by 63.1% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 632,214 shares of the biotechnology company’s stock valued at $11,886,000 after acquiring an additional 244,527 shares in the last quarter. Northern Trust Corp raised its stake in shares of Arrowhead Pharmaceuticals by 11.4% in the fourth quarter. Northern Trust Corp now owns 1,484,419 shares of the biotechnology company’s stock valued at $27,907,000 after acquiring an additional 151,654 shares in the last quarter. Tudor Investment Corp ET AL raised its stake in shares of Arrowhead Pharmaceuticals by 6.6% in the fourth quarter. Tudor Investment Corp ET AL now owns 66,573 shares of the biotechnology company’s stock valued at $1,252,000 after acquiring an additional 4,149 shares in the last quarter. Aquatic Capital Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 80.9% in the fourth quarter. Aquatic Capital Management LLC now owns 169,394 shares of the biotechnology company’s stock valued at $3,185,000 after acquiring an additional 75,776 shares in the last quarter. Finally, Dark Forest Capital Management LP raised its stake in shares of Arrowhead Pharmaceuticals by 82.6% in the fourth quarter. Dark Forest Capital Management LP now owns 172,623 shares of the biotechnology company’s stock valued at $3,245,000 after acquiring an additional 78,078 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 32,729 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the transaction, the insider now directly owns 272,122 shares in the company, valued at $5,393,458.04. This trade represents a 10.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William D. Waddill sold 3,748 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the transaction, the director now owns 44,125 shares of the company’s stock, valued at approximately $966,337.50. This represents a 7.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 147,432 shares of company stock worth $2,957,986 over the last ninety days. Company insiders own 4.30% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.